Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin

被引：4
|
作者：
Estrin, A. [1 ]
Wang, X. [2 ]
Boccuti, A. [3 ]
Prince, P. [1 ]
Gautam, N. [1 ]
Rengarajan, B. [3 ]
Li, W. [2 ]
Lu, T. [3 ]
Cao, Y. [2 ]
Naveh, N. [2 ]
D'Agostino, R. [4 ]
Ben-Joseph, R. [3 ]
Ganti, A. K. [5 ]
机构：
[1] Aetion Inc, Sci, New York, NY USA
[2] Jazz Pharmaceut, Med Affairs, Philadelphia, PA USA
[3] Jazz Pharmaceut, Med Affairs, Palo Alto, CA USA
[4] Wake Forest Univ Sch Med, Biostat & Data Sci, Winston Salem, NC USA
[5] Univ Nebraska Med Ctr, VA Nebraska Western Iowa Hlth Care Syst, Nebraska Med Ctr, Omaha, NE USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1539P
引用
收藏
页码：S1250 / S1250
页数：1
相关论文
共 50 条
  • [21] Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
    Panagiotou, E.
    Livanou, M. E.
    Montgomery, A.
    Mastrogeorgiou, M.
    Moeckel, C.
    Syrigos, N.
    Mouratidis, I.
    Charpidou, A.
    Georgakopoulos-Soares, I.
    Vathiotis, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [22] An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
    Patel, Shetal
    Petty, William Jeffrey
    Sands, Jacob M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [23] Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.
    Rizzo, Alessandro
    Salati, Massimiliano
    Frega, Giorgio
    Merz, Valeria
    Caputo, Francesco
    Ricci, Angela Dalia
    Palloni, Andrea
    Messina, Carlo
    Spallanzani, Andrea
    Saccoccio, Gioconda
    Mollica, Veronica
    Gelsomino, Fabio
    Benatti, Stefania
    Luppi, Gabriele
    Melisi, Davide
    Dominici, Massimo
    Brandi, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [24] Outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated in second line (2L) in the US real-world setting
    Luhn, P.
    O'Hear, C.
    Ton, T. G.
    Hsieh, A.
    Yi, J.
    Chang, C-W
    Funke, R.
    Kurian, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [25] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Cheng, Ying
    Wu, Chunjiao
    Wu, Lin
    Zhao, Jun
    Zhao, Yanqiu
    Chen, Lulu
    Xin, Ying
    Zhang, Liang
    Pan, Pinhua
    Li, Xingya
    Li, Juan
    Dong, Xiaorong
    Tang, Ke
    Gao, Emei
    Yu, Fei
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [26] A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer
    Ying Cheng
    Chunjiao Wu
    Lin Wu
    Jun Zhao
    Yanqiu Zhao
    Lulu Chen
    Ying Xin
    Liang Zhang
    Pinhua Pan
    Xingya Li
    Juan Li
    Xiaorong Dong
    Ke Tang
    Emei Gao
    Fei Yu
    Scientific Reports, 14
  • [27] Real-world patient eligibility for lurbinectedin/doxorubicin in small cell lung cancer
    Rittberg, R.
    Leung, B.
    Al-Hashami, Z.
    Ho, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S101 - S102
  • [28] Second-line (2L) real-world treatment (tx) patterns and outcomes in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) treated with first-line (1L) immuno-oncology (IO) monotherapy (mono tx)
    Talbot, D.
    Fish, S. M.
    Ong, T. Jin
    Flick, E. D.
    Waterhouse, D. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
    Gray, Jhanelle E.
    Hsu, Hil
    Younan, Diana
    Suri, Gaurav
    Chia, Victoria
    Spira, Alexander
    Johnson, Melissa
    LUNG CANCER, 2023, 181
  • [30] Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC)
    Cramer-van der Welle, Christine
    Schramel, Franz M. N. H.
    Van Leeuwen, Arvid S.
    Klungel, Olaf H.
    Groen, Harry J. M.
    Van de Garde, Ewoudt M. W.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
12345